Bicara Therapeutics (BCAX) vs Oric Pharmaceuticals (ORIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bicara Therapeutics (BCAX) has outperformed Oric Pharmaceuticals (ORIC) over the past year, losing 9.6% versus a loss of 14.9%. Oric Pharmaceuticals is the larger company by market cap ($1.24 billion vs $1.14 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | ORIC |
|---|---|---|
| Share price | $17.20 | $11.99 |
| Market cap | $1.14B | $1.24B |
| 1-day change | +4.72% | -0.21% |
| YTD return | -2.44% | +46.82% |
| 1-year return | -9.63% | -14.94% |
| 5-year return | — | -26.00% |
| EPS (TTM) | $-3.08 | $-1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.99 | $14.68 |
| 52-week low | $13.70 | $7.23 |
| Distance from 52-week high | -44.51% | -18.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +106.46% | +78.81% |
| Average volume | 610.46K | 1.45M |
| Shares outstanding | 66.17M | 103.65M |
| Employees | 103 | 111 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
BCAX vs ORIC FAQ
Which is bigger, Bicara Therapeutics or Oric Pharmaceuticals?
Oric Pharmaceuticals (ORIC) is larger, with a market capitalization of $1.24B compared with $1.14B for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, BCAX or ORIC?
BCAX returned -9.63% over the past 12 months, compared with -14.94% for ORIC (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Oric Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.